Members of the COW Board participate in a volunteer capacity. They are not compensated for their role in overseeing the program. Listed below are the COW Board members.
Board Co-Chairs
Michael S. Saag, MD
Professor of Medicine
University of Alabama at Birmingham
Birmingham, Alabama
Dr Saag reported serving as a consultant to TFF Pharmaceuticals and American Gene Technologies International, Inc. (Updated May 25, 2023)
Marshall J. Glesby, MD, PhD
Professor of Medicine and Healthcare Policy and Research
Weill Cornell Medicine
New York, New York
Dr Glesby reported research grants awarded to his institution from Gilead Sciences, Inc; and reported serving as a consultant to ReAlta Life Sciences, Inc. (Updated July 21, 2023)
Board Members
Roger J. Bedimo, MD, MS
Professor of Internal Medicine
University of Texas Southwestern Medical Center
Dallas, Texas
Dr Bedimo reported research grants awarded to his institution from Merck & Co, Inc; and reported serving on the scientific advisory boards of Merck & Co, Inc, ViiV Healthcare, Gilead Sciences, Inc., Theratechnologies, Inc., Shionogi & Co., and Janssen Pharmaceuticals. (Updated April 27, 2023)
Kara W. Chew, MD, MS
Assistant Clinical Professor of Medicine
University of California Los Angeles David Geffen School of Medicine
Los Angeles, California
Dr Chew reported consulting or advising fees from Pardes Biosciences; research grants/grants pending to herself from Merck Sharp & Dohme. (Updated May 28, 2023)
Betty J. Dong, PharmD
Professor of Clinical Pharmacy
University of California San Francisco
San Francisco, California
Dr Dong reported no relevant financial relationships with ineligible companies. (Updated December 12, 2022)
Steven C. Johnson, MD
Professor of Medicine
University of Colorado School of Medicine
Aurora, Colorado
Dr Johnson has no relevant financial relationships with ineligible companies to disclose. (Updated May 24, 2023)
Carrie Down Johnston, MD
Instructor in Medicine
Weill Cornell Medicine
New York, New York
Dr Johnston reported consultant or advisor fees from Theratechnologies, Inc. (Updated May 25, 2023)
Harry W. Lampiris, MD
Professor of Clinical Medicine
University of California San Francisco
San Francisco, California
Dr Lampiris has no relevant financial relationships with ineligible companies to disclose. (Updated April 11, 2023)
David L. Wyles, MD
Chief of the Division of Infectious Diseases
Denver Health Medical Center
Denver, Colorado
Dr Wyles reported serving as a consultant to, receiving payment for lectures from, and receiving grant support awarded to his institution from Gilead Sciences, Inc.; serving as an advisor to AbbVie (Updated August 22, 2023)
Planner
Donna M. Jacobsen
Executive Director/President
International Antiviral Society–USA
San Francisco, California
Ms Jacobsen reported no relevant financial relationships with ineligible companies. (Updated August 1, 2023)